# A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus

> **NCT02305810** · PHASE2 · COMPLETED · sponsor: **European Institute of Oncology** · enrollment: 54 (actual)

## Conditions studied

- Pancreatic Neuroendocrine Tumour Metastatic

## Interventions

- **DRUG:** Everolimus 10 mg daily

## Key facts

- **NCT ID:** NCT02305810
- **Lead sponsor:** European Institute of Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09
- **Primary completion:** 2017-01-12
- **Final completion:** 2018-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2018-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02305810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02305810, "A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02305810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*